explore -WSS

explore

author：explore 2025-10-01 23:00:23 - browse：57694

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： 'Brian's Song' at 50 still offers lessons about cancer for today

focus

WSS

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Stanford president's case begs question: Who takes blame?

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Judge in Trump's classified documents case questions use of out

Mass General totes up its waste in a move to tackle climate change

Judge rejects Trump's request to move Stormy Daniels hush

hotspot

explore

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Bright Health sells Medicare Advantage business to Molina

Doctors are clamoring for more clarity on Paxlovid prescribing

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Divers poised to search for children washed away in Pennsylvania flash flood

Cancer drug shortages should be causing more outrage

Vir antibody drug aimed at influenza A fails in clinical trial

Hepatitis C has a cure — but many Americans still lack access to it

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Wikipedia

It was time to plan for my old age. If only I could stop crying

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

EF3 tornado rips through North Carolina amid extreme weather nationwide

Study identifies new proteins linked to dementia risk 25 years later

Why Congress must ban federal programs from using QALYs

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

focus

leisure time

leisure time

leisure time